| [1] |
Arber DA, Orazi A, Hasserjian R , et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016,127(20):2391-2405.
|
| [2] |
Willman CL, Busque L, Griffith BB , et al. Langerhans’-cell histiocytosis (histiocytosis X): a clonal proliferative disease[J]. N Engl J Med, 1994,331(3):154-160.
|
| [3] |
Allen CE, Li LN, Peters TL , et al. Cell-specific gene expression in Langerhans cell Histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells[J]. J Immunol, 2010,184(8):4557-4567.
|
| [4] |
Bubolz AM, Weissinger SE, Stenzinger A , et al. Potential clinical implications of BRAF mutations in histiocytic proliferations[J]. Oncotarget, 2014,5(12):4060-4070.
|
| [5] |
许霞, 聂秀 . 朗格汉斯细胞组织细胞增生症发病机制的研究进展[J]. 临床与实验病理学杂志, 2015,31(12):1392-1395.
|
|
Xu X, Nie X . Progress on the pathogenesis of Langerhans cell histiocytosis[J]. Chin J Clin Exp Pathol, 2015,31(12):1392-1395.
|
| [6] |
Davies H, Bignell GR, Cox C , et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002,417(6892):949-954.
|
| [7] |
Haroche J, Cohen-Aubart F, Emile JF , et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell Histiocytosis harboring the BRAF V600E mutation[J]. Blood, 2013,121(9):1495-1500.
|
| [8] |
Chou T, D’Angio GJ, Favara BE , et al. Histiocytosis syndromes in children. Writing group of the histiocyte society[J]. Lancet, 1987,1(8526):208-209.
|
| [9] |
Brabencova E, Tazi A, Lorenzato M , et al. Langerhans cells in Langerhans cell granulomatosis are not actively proliferating cells[J]. Am J Pathol, 1998,152(5):1143-1149.
|
| [10] |
Valladeau J, Ravel O, Dezutter-Dambuyant C , et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules[J]. Immunity, 2000,12(1):71-81.
|
| [11] |
Chikwava K, Jaffe R . Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders[J]. Pediatr Dev Pathol, 2004,7(6):607-614.
|
| [12] |
Lau SK, Chu PG, Weiss LM . Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders[J]. Am J Surg Pathol, 2008,32(4):615-619.
|
| [13] |
Krooks J, Minkov M, Weatherall AG . Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up[J]. J Am Acad Dermatol, 2018,78(6):1047-1056.
|
| [14] |
Krooks J, Minkov M, Weatherall AG . Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis[J]. J Am Acad Dermatol, 2018,78(6):1035-1044.
|
| [15] |
周云, 刘秋玲 . 朗格汉斯细胞组织细胞增生症的发病机制及诊治进展[J]. 中华灾害救援医学, 2017,5(2):106-110.
|
|
Zhou Y, Liu QL . Progress on Langerhans cell Histiocytosis: pathogenesis, diagnosis and treatment[J]. Chin J Disaster Med, 2017,5(2):106-110.
|
)
This work is licensed under a Creative Commons Attribution 3.0 License.
